| 英文名稱 | Anti-Human IGF1RxHer3 Bispecific Antibody (Istiratumab; MM 141; MM-005) |
|---|---|
| 中文名稱 | 艾司妥單抗 |
| CAS號 | 1509928-04-4 |
| 規(guī)格 | 庫存 | 目錄價(jià) | 會員專享價(jià) | 數(shù)量 | |
|---|---|---|---|---|---|
|
暫無牌價(jià)信息,您可以發(fā)送詢價(jià),我們會盡快給你回復(fù)。 |
|||||
| 英文名稱 | Anti-Human IGF1RxHer3 Bispecific Antibody (Istiratumab; MM 141; MM-005) |
|---|---|
| 中文名稱 | 艾司妥單抗 |
| CAS號 | 1509928-04-4 |
Istiratumab, a bispecific mAb against IGF-1R and ErbB3, promotes receptor degradation via proteasomes, inhibiting AKT in pancreatic cancer cells and blocking PI3K/MAPK in ovarian cancer. It enhances chemo efficacy, potentiating paclitaxel, cisplatin, and doxorubicin in preclinical studies.
PMID: 31912800 DOI: 10.1016/j.annonc.2019.09.004
PMID: 29549161 DOI: 10.1158/1078-0432.CCR-17-2262
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
PMID: 31728045 PMCID: PMC6856132 DOI: 10.1038/s41598-019-53322-y